Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04645940 · ClinicalTrials.gov registry record · Phase 1
Fruquintinib Food Effect and Proton Pump Inhibitor Study
A Phase 1 study of Drug Interaction and Food-drug Interaction, sponsored by Hutchison Medipharma Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04645940: Completed Phase 1 study of Drug Interaction and Food-drug Interaction, sponsored by Hutchison Medipharma Limited.
NCT04645940 is a Phase 1 study of Drug Interaction and Food-drug Interaction that has completed, run by Hutchison Medipharma Limited. The registered enrollment target is 14 participants, below the 94-participant average among 3 other Drug Interaction trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04645940, a Phase 1 study of Drug Interaction and Food-drug Interaction, has completed, sponsored by Hutchison Medipharma Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this is to evaluate the effect of food and the effect of a proton pump inhibitor (rabeprazole) on the pharmacokinetics of fruquintinib.
Primary Outcome
Pharmacokinetics of fruquintinib by assessment of area under the plasma concentration time curve from zero to the last measurable concentration
Conditions Studied
Interventions
- DRUG fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole
- DRUG fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole
Study Locations (1)
California
- WCCT - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-09-24 |
| Est. Completion | 2020-11-18 |
| Phase | Phase 1 |
What the finished NCT04645940 record still lists
NCT04645940 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 94-participant average among 3 other Drug Interaction trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Drug Interaction appearing as the primary indexed condition, and to 2 interventions - of which fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole is the first listed.
NCT04645940 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04645940 about?
NCT04645940 is a clinical study titled "Fruquintinib Food Effect and Proton Pump Inhibitor Study". The purpose of this is to evaluate the effect of food and the effect of a proton pump inhibitor (rabeprazole) on the pharmacokinetics of fruquintinib.
What is the current status of trial NCT04645940?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2020-09-24. Estimated completion is 2020-11-18.
What conditions does trial NCT04645940 study?
This clinical trial studies the following conditions: Drug Interaction, Food-drug Interaction.
What interventions are being tested in trial NCT04645940?
The interventions under investigation include: fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole (DRUG), fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole (DRUG).
Who is sponsoring clinical trial NCT04645940?
This trial is sponsored by Hutchison Medipharma Limited, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04645940 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Interaction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy